OPTHEA LIMITED (OPT)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

OPT - OPTHEA LIMITED

FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: -1.03
Index: ASX300 | ALL-ORDS

Opthea is an Australian healthcare company specialising in the development and commercialisation of therapies to combat eye diseases. Founded in 1984, the company listed on the ASX in 1991.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.61

22 Nov
2024

-0.015

OPEN

$0.62

-2.40%

HIGH

$0.63

1,666,247

LOW

$0.60

TARGET
$1.30 113.1% upside
OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGH . AGN . ARX . AVH . BIO . BOT . CSL . CUV . DXB . EOF . GSS . HXL . IDT . IMM . IMU . IVX . LGP . MAP . MDC . MSB . MVP . MYX . NEU . NUZ . NXS . OCC . OSL . PAR . PER . PNV . PYC . RAC . RCE . SPL . TLX . TRP . VIT . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS
OPT: 1
Title FY23
Actual		 FY24
Actual		 FY25
Forecast		 FY26
Forecast
EPS (cps) xxx - 52.7 - 21.4 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A N/A xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title 201920202021202220232024
EPS Basic xxxxxxxxxxxxxxx-52.7
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx0.2 M
Book Value Per Share xxxxxxxxxxxxxxx-10.4
Net Operating Cash Flow xxxxxxxxxxxxxxx-245.7 M
Net Profit Margin xxxxxxxxxxxxxxx-176,665.73 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201920202021202220232024
Return on Capital Employed xxxxxxxxxxxxxxx-
Return on Invested Capital xxxxxxxxxxxxxxx-377.45 %
Return on Assets xxxxxxxxxxxxxxx-156.01 %
Return on Equity xxxxxxxxxxxxxxx-
Return on Total Capital xxxxxxxxxxxxxxx-328.49 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-245.8 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201920202021202220232024
Short-Term Debt xxxxxxxxxxxxxxx0 M
Long Term Debt xxxxxxxxxxxxxxx300 M
Total Debt xxxxxxxxxxxxxxx300 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx258 M
Price To Book Value xxxxxxxxxxxxxxx-

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201920202021202220232024
Capex xxxxxxxxxxxxxxx0.1 M
Capex % of Sales xxxxxxxxxxxxxxx26.86 %
Cost of Goods Sold xxxxxxxxxxxxxxx0 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx293 M
Research & Development xxxxxxxxxxxxxxx269 M
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

23/09/2024

1

Speculative Buy

$1.30

113.11%

While leaving forecasts unchanged for Opthea, Bell Potter raises the probability of success. Along with ongoing clinical trials, management has now completed multiple commercial scale manufacturing batches of the sozinibercept drug substance.

Manufacturing has been at a commercial scale using a reproducible process that generated consistent product quality, explains the broker.

This progress suggests to the analysts management should be well placed to submit a Biologics Licence Application (BLA) package to the FDA relatively swiftly after Phase 3 topline results are available.

The Speculative Buy rating is maintained, and the target is increased to $1.30 from 70c.

FORECAST
Bell Potter forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -21.40 cents.
Bell Potter forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -21.80 cents.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

0

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY
Access Extra Coverage Research History >

OPT STOCK CHART

FNArena News on OPT

1
Next Week At A Glance – 26-30 – Aug 2024

Aug 23 2024 - Weekly Reports
2
Rudi’s View: February 2024 Is A Blue Sky Affair

Feb 14 2024 - Rudi's View
3
Australian Broker Call *Extra* Edition – Oct 18, 2023

Oct 18 2023 - Daily Market Reports
4
Australian Broker Call *Extra* Edition – Aug 30, 2023

Aug 30 2023 - Daily Market Reports
5
Australian Broker Call *Extra* Edition – Jul 27, 2023

Jul 27 2023 - Daily Market Reports

Latest Pharmaceuticals & Biotech/Lifesciences News

1
Dr Boreham’s Crucible: Arovella Therapeutics

Aug 29 2024 - Small Caps
2
ResMed’s Margin Upside Excites

Aug 07 2024 - Australia
3
Dr Boreham’s Crucible: Aroa Biosurgery

Jul 29 2024 - Small Caps
4
CSL Shares Breaking Free

Jul 23 2024 - Technicals
5
Dr Boreham’s Crucible: SDI

Jul 19 2024 - Small Caps
6
‘Defensive’ Pharmaceutical Wholesalers In Focus

Jul 18 2024 - Australia
7
Twists And Turns Of Telix And Australian Biotech

Jul 10 2024 - Small Caps
8
Dr Boreham’s Crucible: Radiopharm Theranostics

Jul 03 2024 - Small Caps
9
Dr Boreham’s Crucible: Island Therapeutics

Jun 17 2024 - Small Caps
10
Dr Boreham’s Crucible: Amplia Therapeutics

Jun 05 2024 - Small Caps